Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study

Wonseok Lee, Sunghoon Lee, Hyoung Won Bae, Chan Yun Kim, Gong Je Seong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost using a prospective crossover study. Methods: Primary open angle glaucoma (POAG) and normotensive glaucoma (NTG) patients were randomized enrolled. Group 1 (“NPT to PT”) patients used preservative-free 0.0015% tafluprost (NPT) for 6 months and then changed to preservative containing 0.0015% tafluprost(PT) for 6 months. Group 2 (“PT to NPT”) patients used preservative containing 0.0015% tafluprost for 6 months and changed to preservative-free 0.0015% tafluprost for 6 months. At 1, 3, 6, 7, 9, and 12 months, we measured intraocular pressure for efficacy and graded corneal erosion, tear break-up time (TBUT), and subjective discomfort. Results: A total of 20 patients and 20 eyes were enrolled. In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease). Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT. Conclusion: Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly. In addition, changing medication from PT to NPT might improve subjective satisfaction and tear break up time. Trial registration: The trial registration number is NCT 03104621 (Apr/1/2017). Retrospectively registered.

Original languageEnglish
Article number61
JournalBMC Ophthalmology
Volume17
Issue number1
DOIs
Publication statusPublished - 2017 Apr 28

Fingerprint

Glaucoma
Cross-Over Studies
Prospective Studies
Tears
Intraocular Pressure
tafluprost

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

@article{269ec148bd5a450a94c6fd8fe21bf89c,
title = "Efficacy and tolerability of preservative-free 0.0015{\%} tafluprost in glaucoma patients: a prospective crossover study",
abstract = "Background: The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015{\%} tafluprost and preservative-free 0.0015{\%} tafluprost using a prospective crossover study. Methods: Primary open angle glaucoma (POAG) and normotensive glaucoma (NTG) patients were randomized enrolled. Group 1 (“NPT to PT”) patients used preservative-free 0.0015{\%} tafluprost (NPT) for 6 months and then changed to preservative containing 0.0015{\%} tafluprost(PT) for 6 months. Group 2 (“PT to NPT”) patients used preservative containing 0.0015{\%} tafluprost for 6 months and changed to preservative-free 0.0015{\%} tafluprost for 6 months. At 1, 3, 6, 7, 9, and 12 months, we measured intraocular pressure for efficacy and graded corneal erosion, tear break-up time (TBUT), and subjective discomfort. Results: A total of 20 patients and 20 eyes were enrolled. In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46{\%} decrease). Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT. Conclusion: Both preservative containing and preservative-free 0.0015{\%} tafluprost reduced intraocular pressure significantly. In addition, changing medication from PT to NPT might improve subjective satisfaction and tear break up time. Trial registration: The trial registration number is NCT 03104621 (Apr/1/2017). Retrospectively registered.",
author = "Wonseok Lee and Sunghoon Lee and Bae, {Hyoung Won} and Kim, {Chan Yun} and Seong, {Gong Je}",
year = "2017",
month = "4",
day = "28",
doi = "10.1186/s12886-017-0453-z",
language = "English",
volume = "17",
journal = "BMC Ophthalmology",
issn = "1471-2415",
publisher = "BioMed Central",
number = "1",

}

Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients : a prospective crossover study. / Lee, Wonseok; Lee, Sunghoon; Bae, Hyoung Won; Kim, Chan Yun; Seong, Gong Je.

In: BMC Ophthalmology, Vol. 17, No. 1, 61, 28.04.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients

T2 - a prospective crossover study

AU - Lee, Wonseok

AU - Lee, Sunghoon

AU - Bae, Hyoung Won

AU - Kim, Chan Yun

AU - Seong, Gong Je

PY - 2017/4/28

Y1 - 2017/4/28

N2 - Background: The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost using a prospective crossover study. Methods: Primary open angle glaucoma (POAG) and normotensive glaucoma (NTG) patients were randomized enrolled. Group 1 (“NPT to PT”) patients used preservative-free 0.0015% tafluprost (NPT) for 6 months and then changed to preservative containing 0.0015% tafluprost(PT) for 6 months. Group 2 (“PT to NPT”) patients used preservative containing 0.0015% tafluprost for 6 months and changed to preservative-free 0.0015% tafluprost for 6 months. At 1, 3, 6, 7, 9, and 12 months, we measured intraocular pressure for efficacy and graded corneal erosion, tear break-up time (TBUT), and subjective discomfort. Results: A total of 20 patients and 20 eyes were enrolled. In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease). Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT. Conclusion: Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly. In addition, changing medication from PT to NPT might improve subjective satisfaction and tear break up time. Trial registration: The trial registration number is NCT 03104621 (Apr/1/2017). Retrospectively registered.

AB - Background: The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost using a prospective crossover study. Methods: Primary open angle glaucoma (POAG) and normotensive glaucoma (NTG) patients were randomized enrolled. Group 1 (“NPT to PT”) patients used preservative-free 0.0015% tafluprost (NPT) for 6 months and then changed to preservative containing 0.0015% tafluprost(PT) for 6 months. Group 2 (“PT to NPT”) patients used preservative containing 0.0015% tafluprost for 6 months and changed to preservative-free 0.0015% tafluprost for 6 months. At 1, 3, 6, 7, 9, and 12 months, we measured intraocular pressure for efficacy and graded corneal erosion, tear break-up time (TBUT), and subjective discomfort. Results: A total of 20 patients and 20 eyes were enrolled. In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease). Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT. Conclusion: Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly. In addition, changing medication from PT to NPT might improve subjective satisfaction and tear break up time. Trial registration: The trial registration number is NCT 03104621 (Apr/1/2017). Retrospectively registered.

UR - http://www.scopus.com/inward/record.url?scp=85018170441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018170441&partnerID=8YFLogxK

U2 - 10.1186/s12886-017-0453-z

DO - 10.1186/s12886-017-0453-z

M3 - Article

C2 - 28454526

AN - SCOPUS:85018170441

VL - 17

JO - BMC Ophthalmology

JF - BMC Ophthalmology

SN - 1471-2415

IS - 1

M1 - 61

ER -